Skip to main content
Equibles

UBS Group AG

Position in PROK — Prokidney Corp.

CIK 1610520 ZURICH, V8
Back to PROK Full portfolio

Position in PROK

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$1,369,751
+$770,915 QoQ
Shares Held
671,447
+100.7% QoQ
Ownership
0.222%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#13
of 70 holders
Holding Since
Dec 2021
6 quarters on record
Voting authority Sole 96% Shared 0% None 4%

Common Shares in PROK Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

UBS Group AG holds $8,789,675,806 across 561 Biotechnology names. PROK ranks #245 (0.0% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 RVMD
Revolution Medicines, Inc.
 5,450,825 $1,020,369,609
2 ROIV
Roivant Sciences Ltd.
 17,466,641 $618,144,423
3 PTGX
Protagonist Therapeutics, Inc
 3,399,221 $416,676,508
4 VRTX
Vertex Pharmaceuticals Inc / Ma
 712,259 $353,800,411
5 MRNA
Moderna, Inc.
 4,463,211 $312,558,664
6 INSM
INSMED Inc
 2,584,446 $275,553,630
7 ABVX
Abivax S.A.
 1,844,918 $245,853,771
8 MDGL
Madrigal Pharmaceuticals, Inc.
 401,708 $215,697,109

All Filings in PROK

Export CSV
4 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $1,369,751 671,447
2026-03-31 $598,836 334,546
2025-12-31 $933,046 416,539
2025-09-30 $1,230,212 508,353